Dr. Stan Louie is a clinical and translational pharmacologist with over three decades of clinical and drug development experience. His research focus has been drug development for inflammatory diseases which include viral infections, cancer, diabetes, traumatic brain injuries, and neurodegenerative diseases. His focus has included dissecting fundamental causes leading to diseases and developing drug therapies to manage these conditions.
A graduate of UCSF in 1987, Dr. Louie continued his clinical training at California Pacific Medical Center (CPMC). After his residency training, Dr. Louie accepted a position at University of Southern California, where he began his academic career investigating cancer therapy and bone marrow transplantation.
He is a translational scientist who advances new chemical and biological candidates through preclinical in vitro and animal evaluation, which ultimately progress these programs into human clinical trials. Currently the Deputy Director of the Ginsburg Institute of Biomedical Technology at USC, where he is forging efforts to translate basic science discovery into clinical reality. For these efforts, he has developed screening methods for each platform, and developed strategies to iteratively optimize the lead candidates into compounds possessing a balance between maximized stability, safety and maximal efficacy.
His laboratory focuses on drug development for the treatment of virally linked diseases such as HIV and virally linked tumors (e.g., HTLV-linked leukemia, Kaposi’s sarcoma). Efforts in the laboratory crosses a number of therapeutic areas include 1) drug development for viral infections and cancer, 2) new chemical entity development targeting cellular adaptive mechanisms such as autophagy and endoplasmic reticulum stress and 3) development of light activated drug (nanocaged) for the treatment of traumatic brain injury and ophthalmologic injury, and 4) modulators of chronic inflammation using bioactive lipids and cellular derived products for retinal degenerative diseases.
Dr. Louie was a member of the National Institute of Health funded AIDS Clinical Trials Group (ACTG) and the Southwest Oncology Group (SWOG). In addition, he is leading the PharmacoAnalytical Laboratory that can provide GLP bioanalytical studies for collaborators who are working on IND enabling studies. Additionally, he is developing clinical biomarkers to evaluate the impact of new therapeutics candidates in humans.